Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Otsuka's POCARI Drink Inhibits Increases in Blood Viscosity
March 11, 2002
- SSRI 20th Anniversary Seminar
March 11, 2002
- Sunstar to Report Anti-allergic Effects of Persimmon Leaf Extract
March 11, 2002
- RAD-AR Proposes to Korosho to Use Reexamination Data to Construct Database
March 11, 2002
- Administration Restrictions on IFN Lifted
March 4, 2002
- Abolition of Long-term Admission Fees from Insurance Coverage Hits Hospitals:Dr Itouji of JMA
March 4, 2002
- Korosho Calls on Medical Professionals to Cooperate in Immediate PMS
March 4, 2002
- Bungyo Rate Increases to 44.9% in October 2001
March 4, 2002
- REGULATORY NEWS IN BRIEF
March 4, 2002
- AJHA Holds 1st Seminar on TQM
March 4, 2002
- BULLETIN
March 4, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 4, 2002
- Spin-off of Manufacturing Plants to Increase: PAL Revision
March 4, 2002
- 12,558 Drugstores Operated by 590 Companies: JACDS Survey
March 4, 2002
- Study Group Proposes Proper Drug Distribution System
March 4, 2002
- Taisho Appeals against Daikoku
March 4, 2002
- Manufacturers' FTC Issues Guide Regarding Entertainment
March 4, 2002
- Additional Premiums to Be Introduced in Medical Material Pricing System
March 4, 2002
- Kyowa Hakko to Transfer Its Liquor Business to Asahi Breweries
March 4, 2002
- Medical Devices to Be Re-priced to Reduce Domestic, Foreign Price Gaps
March 4, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…